Trial Profile
The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary) ; Morphine
- Indications Opioid-related disorders
- Focus Therapeutic Use
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 07 Sep 2014 Columbia University and the New York State Psychiatric Institute have received a grant from the National Institute on Drug Abuse (NIDA) to enable completion of this trial.
- 18 Aug 2014 Results published in the Media Release.